Literature DB >> 1885424

The pharmacokinetics of cefuroxime axetil in the sick elderly patient.

E Ridgway1, K Stewart, G Rai, M C Kelsey, C Bielawska.   

Abstract

The pharmacokinetics of cefuroxime axetil (RS3 formulation) were studied in 20 elderly patients following admission for lower respiratory or urinary tract infection. The mean age was 83.9 years. A 12-hourly dose of 250 mg was given for five days. The mean time to attain maximum serum concentration was 3.2 h with a mean peak concentration of 8.5 mg/l. The mean serum elimination half-life was 3.5 h and the AUC0-infinity 60.4 mg/h.l. There was no accumulation of the drug in the patients studied after five days treatment. The data suggest that the standard dosage regimen is adequate in the sick elderly patient.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1885424     DOI: 10.1093/jac/27.5.663

Source DB:  PubMed          Journal:  J Antimicrob Chemother        ISSN: 0305-7453            Impact factor:   5.790


  4 in total

Review 1.  Pharmacoeconomics of intravenous drug administration.

Authors:  S E Parker; P G Davey
Journal:  Pharmacoeconomics       Date:  1992-02       Impact factor: 4.981

2.  Intragastric floating drug delivery system of cefuroxime axetil: In vitro evaluation.

Authors:  Viral F Patel; Natavarlal M Patel
Journal:  AAPS PharmSciTech       Date:  2017-03-08       Impact factor: 3.246

3.  Nonlinear intestinal absorption kinetics of cefuroxime axetil in rats.

Authors:  N Ruiz-Balaguer; A Nacher; V G Casabo; M Merino
Journal:  Antimicrob Agents Chemother       Date:  1997-02       Impact factor: 5.191

Review 4.  Cefuroxime axetil. A review of its antibacterial activity, pharmacokinetic properties and therapeutic efficacy.

Authors:  C M Perry; R N Brogden
Journal:  Drugs       Date:  1996-07       Impact factor: 9.546

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.